These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9617979)

  • 1. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study.
    Silver H; Shmugliakov N
    J Clin Psychopharmacol; 1998 Jun; 18(3):208-11. PubMed ID: 9617979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Use of antidepressant drugs in schizophrenic patients with depression].
    Micallef J; Fakra E; Blin O
    Encephale; 2006; 32(2 Pt 1):263-9. PubMed ID: 16910628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SSRI augmentation of antipsychotic alters expression of GABA(A) receptor and related genes in PMC of schizophrenia patients.
    Silver H; Susser E; Danovich L; Bilker W; Youdim M; Goldin V; Weinreb O
    Int J Neuropsychopharmacol; 2011 Jun; 14(5):573-84. PubMed ID: 21208484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study.
    Niitsu T; Fujisaki M; Shiina A; Yoshida T; Hasegawa T; Kanahara N; Hashimoto T; Shiraishi T; Fukami G; Nakazato M; Shirayama Y; Hashimoto K; Iyo M
    J Clin Psychopharmacol; 2012 Oct; 32(5):593-601. PubMed ID: 22926591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized double-blind study of fluvoxamine and maprotiline in treatment of depression.
    de Jonghe F; Swinkels J; Tuynman-Qua H
    Pharmacopsychiatry; 1991 Jan; 24(1):21-7. PubMed ID: 1901418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to total sleep deprivation before and during treatment with fluvoxamine or maprotiline in patients with major depression--results of a double-blind study.
    Kasper S; Voll G; Vieira A; Kick H
    Pharmacopsychiatry; 1990 May; 23(3):135-42. PubMed ID: 2115680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial.
    Takahashi H; Sugita T; Higuchi H; Shimizu T
    Hum Psychopharmacol; 2002 Mar; 17(2):95-8. PubMed ID: 12404698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological dissection of anxiety disorders: the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine.
    den Boer JA; Westenberg HG; De Leeuw AS; van Vliet IM
    Int Clin Psychopharmacol; 1995 Jan; 9 Suppl 4():47-52. PubMed ID: 7622824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile.
    Martényi F; Dossenbach M; Mraz K; Metcalfe S
    Eur Neuropsychopharmacol; 2001 Jun; 11(3):227-32. PubMed ID: 11418283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline.
    Den Boer JA; Westenberg HG
    Int Clin Psychopharmacol; 1988 Jan; 3(1):59-74. PubMed ID: 2833543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidepressant drugs in anergic schizophrenia. A double-blind cross-over study with maprotiline and placebo.
    Waehrens J; Gerlach J
    Acta Psychiatr Scand; 1980 May; 61(5):438-44. PubMed ID: 6105762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects.
    Kasper S; Dötsch M; Kick H; Vieira A; Möller HJ
    Eur Neuropsychopharmacol; 1993 Mar; 3(1):13-21. PubMed ID: 8471827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine.
    Yoshida K; Higuchi H; Kamata M; Takahashi H; Inoue K; Suzuki T; Itoh K; Ozaki N
    J Psychopharmacol; 2007 Aug; 21(6):650-6. PubMed ID: 17092970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Add-on fluvoxamine and negative symptoms of schizophrenia: analysis of data from augmentation studies in a single center.
    Silver H; Bilker WB
    J Clin Psychopharmacol; 2013 Oct; 33(5):710-1. PubMed ID: 23899641
    [No Abstract]   [Full Text] [Related]  

  • 15. Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.
    Silver H
    Expert Opin Pharmacother; 2004 Oct; 5(10):2053-8. PubMed ID: 15461540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Add-on fluvoxamine improves primary negative symptoms: evidence for specificity from response analysis of individual symptoms.
    Silver H; Aharon N; Kaplan A
    Schizophr Bull; 2003; 29(3):541-6. PubMed ID: 14609247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No effects of antidepressants on negative symptoms in schizophrenia.
    Hinkelmann K; Yassouridis A; Kellner M; Jahn H; Wiedemann K; Raedler TJ
    J Clin Psychopharmacol; 2013 Oct; 33(5):686-90. PubMed ID: 23857309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin reuptake inhibition vs. norepinephrine reuptake inhibition: a double-blind differential-therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives.
    Emrich HM; Berger M; Riemann D; von Zerssen D
    Pharmacopsychiatry; 1987 Mar; 20(2):60-3. PubMed ID: 3108909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: A 12-week, randomized, double-blind, placebo-controlled study.
    Lu ML; Chen TT; Kuo PH; Hsu CC; Chen CH
    Schizophr Res; 2018 Mar; 193():126-133. PubMed ID: 28688742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcl1 polymorphism of the glucocorticoid receptor gene and treatment response to milnacipran and fluvoxamine in Japanese patients with depression.
    Takahashi H; Yoshida K; Higuchi H; Kamata M; Inoue K; Suzuki T; Ishigooka J
    Neuropsychobiology; 2014; 70(3):173-80. PubMed ID: 25358426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.